Saltz, Leonard B.

Tumor mutational load predicts survival after immunotherapy across multiple cancer types

Samstein, R. M., Lee, C.-H., Shoushtari, A. N., Hellmann, M. D., Shen, R., Janjigian, Y. Y., Barron, D. A., Zehir, A., Jordan, E. J., Omuro, A., et al. (2019) · Nature Genetics

Cancer Immunotherapy and BiomarkersCancer Genomics and Diagnostics

Cited by 4,071

Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients

Zehir, A., Benayed, R., Shah, R. H., Syed, A., Middha, S., Kim, H. R., Srinivasan, P., Gao, J., Chakravarty, D., Devlin, S. M., et al. (2017) · Nature Medicine

Cancer Genomics and DiagnosticsBRCA gene mutations in cancer

Cited by 3,380

Bevacizumab in Combination with Oxaliplatin-Based Chemotherapy as First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study

Saltz, L. B., Clarke, S., Díaz-Rubio, E., Scheithauer, W., Figer, A., Wong, R., Koski, S., Lichinitser, M., Yang, T.-S., Rivera, F., et al. (2008) · Journal of Clinical Oncology

Colorectal Cancer Treatments and StudiesColorectal Cancer Surgical Treatments

Cited by 2,955

Phase II Trial of Cetuximab in Patients With Refractory Colorectal Cancer That Expresses the Epidermal Growth Factor Receptor

Saltz, L. B., Meropol, N. J., Loehrer, P. J., Needle, M. N., Kopit, J., & Mayer, R. J. (2004) · Journal of Clinical Oncology

Colorectal Cancer Treatments and StudiesHER2/EGFR in Cancer Research

Cited by 1,694

Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry.

Chung, K. Y., Shia, J., Kemeny, N. E., Shah, M., Schwartz, G. K., Tse, A., Hamilton, A., Pan, D., Schrag, D., Schwartz, L., et al. (2005) · Journal of Clinical Oncology

Colorectal Cancer Treatments and StudiesHER2/EGFR in Cancer Research

Cited by 1,081

Clinical Sequencing Defines the Genomic Landscape of Metastatic Colorectal Cancer

Yaeger, R., Chatila, W. K., Lipsyc, M. D., Hechtman, J. F., Cercek, A., Sanchez-Vega, F., Jayakumaran, G., Middha, S., Zehir, A., Donoghue, M. T. A., et al. (2018) · Cancer Cell

Colorectal Cancer Treatments and StudiesGenetic factors in colorectal cancer

Cited by 858

Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF -Mutated Colorectal Cancer

Kopetz, S., Desai, J., Chan, E., Hecht, J. R., O'Dwyer, P. J., Maru, D., Morris, V., Janku, F., Dasari, A., Chung, W., et al. (2015) · Journal of Clinical Oncology

Colorectal Cancer Treatments and StudiesLung Cancer Treatments and Mutations

Cited by 697

Developing a cancer‐specific geriatric assessment: A feasibility study

Hurria, A., Gupta, S., Zauderer, M., Zuckerman, E. L., Cohen, H. J., Muss, H., Rodin, M., Panageas, K. S., Holland, J. C., Saltz, L., et al. (2005) · Cancer

Frailty in Older AdultsNutrition and Health in Aging

Cited by 623

A rectal cancer organoid platform to study individual responses to chemoradiation

Ganesh, K., Wu, C., O’Rourke, K. P., Szeglin, B. C., Zheng, Y., Sauvé, C.-E. G., Adileh, M., Wasserman, I., Marco, M. R., Kim, A. S., et al. (2019) · Nature Medicine

Cancer Cells and MetastasisColorectal Cancer Surgical Treatments

Cited by 569

Extracellular Metabolic Energetics Can Promote Cancer Progression

Loo, J. M., Scherl, A., Nguyen, A., Man, F. Y., Weinberg, E., Zeng, Z., Saltz, L., Paty, P. B., & Tavazoie, S. F. (2015) · Cell

Cancer, Hypoxia, and MetabolismMicroRNA in disease regulation

Cited by 393

Genomic and Biological Characterization of Exon 4 KRAS Mutations in Human Cancer

Janakiraman, M., Vakiani, E., Zeng, Z., Pratilas, C. A., Taylor, B. S., Chitale, D., Halilovic, E., Wilson, M., Huberman, K., Ricarte Filho, J. C., et al. (2010) · Cancer Research

Protein Kinase Regulation and GTPase SignalingColorectal Cancer Treatments and Studies

Cited by 290

Pilot Trial of Combined BRAF and EGFR Inhibition in BRAF -Mutant Metastatic Colorectal Cancer Patients

Yaeger, R., Cercek, A., O'Reilly, E. M., Reidy, D. L., Kemeny, N., Wolinsky, T., Capanu, M., Gollub, M. J., Rosen, N., Berger, M. F., et al. (2015) · Clinical Cancer Research

Colorectal Cancer Treatments and StudiesMelanoma and MAPK Pathways

Cited by 276

Pooled Safety and Efficacy Analysis Examining the Effect of Performance Status on Outcomes in Nine First-Line Treatment Trials Using Individual Data From Patients With Metastatic Colorectal Cancer

Sargent, D. J., Köhne, C. H., Sanoff, H. K., Bot, B. M., Seymour, M. T., de Gramont, A., Porschen, R., Saltz, L. B., Rougier, P., Tournigand, C., et al. (2009) · Journal of Clinical Oncology

Colorectal Cancer Treatments and StudiesColorectal Cancer Surgical Treatments

Cited by 196

Overspending driven by oversized single dose vials of cancer drugs

Bach, P. B., Conti, R. M., Muller, R. J., Schnorr, G. C., & Saltz, L. B. (2016) · BMJ

Pharmaceutical Economics and PolicyEconomic and Financial Impacts of Cancer

Cited by 156

Randomized, phase II study of the insulin-like growth factor-1 receptor inhibitor IMC-A12, with or without cetuximab, in patients with cetuximab- or panitumumab-refractory metastatic colorectal cancer

Reidy, D. L., Vakiani, E., Fakih, M. G., Saif, M. W., Hecht, J. R., Goodman-Davis, N., Hollywood, E., Shia, J., Schwartz, J., Chandrawansa, K., et al. (2010) · Journal of Clinical Oncology

Colorectal Cancer Treatments and StudiesGrowth Hormone and Insulin-like Growth Factors

Cited by 138

Unusual DNA mismatch repair-deficient tumors in Lynch syndrome: a report of new cases and review of the literature

Karamurzin, Y., Zeng, Z., Stadler, Z. K., Zhang, L., Ouansafi, I., Al-Ahmadie, H. A., Sempoux, C., Saltz, L. B., Soslow, R. A., O'Reilly, E. M., et al. (2012) · Human Pathology

Genetic factors in colorectal cancerBRCA gene mutations in cancer

Cited by 112

Mechanisms of Acquired Resistance to BRAF V600E Inhibition in Colon Cancers Converge on RAF Dimerization and Are Sensitive to Its Inhibition

Yaeger, R., Yao, Z., Hyman, D. M., Hechtman, J. F., Vakiani, E., Zhao, H., Su, W., Wang, L., Joelson, A., Cercek, A., et al. (2017) · Cancer Research

Melanoma and MAPK PathwaysColorectal Cancer Treatments and Studies

Cited by 94

PCK1 and DHODH drive colorectal cancer liver metastatic colonization and hypoxic growth by promoting nucleotide synthesis

Yamaguchi, N., Weinberg, E. M., Nguyen, A., Liberti, M. V., Goodarzi, H., Janjigian, Y. Y., Paty, P. B., Saltz, L. B., Kingham, T. P., Loo, J. M., et al. (2019) · eLife

Cancer, Hypoxia, and MetabolismBiochemical and Molecular Research

Cited by 91

Efficacy of capecitabine versus 5-fluorouracil in colorectal and gastric cancers: A meta-analysis of individual data from 6171 patients

Cassidy, J., Saltz, L., Twelves, C., Van Cutsem, E., Hoff, P., Kang, Y., Saini, J. P., Gilberg, F., & Cunningham, D. (2011) · Annals of Oncology

Colorectal Cancer Treatments and StudiesGastric Cancer Management and Outcomes

Cited by 90

BRAF Mutations in Colorectal Cancer: Clinical Relevance and Role in Targeted Therapy

Yaeger, R., & Saltz, L. (2012) · Journal of the National Comprehensive Cancer Network

Colorectal Cancer Treatments and StudiesColorectal Cancer Surgical Treatments

Cited by 18